Golden Helix Inc. Announces the Release of VSWarehouse for Genetic Data Warehousing

Bozeman, MT (February 3, 2016) — Today, Golden Helix announced the upcoming release of VSWarehouse, the company’s newest software solution for genetic data warehousing.

Coming in March, VSWarehouse is a state-of-the-art, scalable, multi-project warehouse for NGS variant call sets, clinical reports and catalogs of variant assessments. VSWarehouse will allow labs to manage the massive data sets and leverage the highly valuable information that is generated by next-generation sequencing. Clinicians and researchers alike will be able to use the data that is created on a day-to-day basis as a reference point as well as be alerted of new research.

“We evaluated several solutions to implement in the Shivanand R. Patil Cytogenetics and Molecular Laboratory”, said Dr. Benjamin Darbro of the University of Iowa. “VarSeq’s clinical suite had everything we were looking for. And I could not be more impressed with the Golden Helix team and their responsiveness to our lab’s needs.”

“Any lab who is serious about NGS sequencing requires the ability to use its data on an ongoing basis as a knowledge base”, says Dr. Andreas Scherer, CEO & President of Golden Helix. “Labs also need flexible ways to query growing datasets for future research as well as an infrastructure that connects the lab with the overall hospital and other IT systems. VSWarehouse is the answer to all of these problems.”

About Golden Helix
Golden Helix has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over 17 years. Our innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing. With our solutions, hundreds of the world’s top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 900 peer-reviewed publications. For more information, visit: /

Cheryl Rogers
Director of Marketing
Golden Helix, Inc.
406-585-8137
rogers@goldenhelix.com